Brian Camilleri

Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT)

Julie Bernhardt, Leonid Churilov, Fiona Ellery et al. · Neurology · 2016 · 210 citations · Full text

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Rona Smith, Rachel Jones, Ulrich Specks et al. · Annals of the Rheumatic Diseases · 2020 · 168 citations · Full text

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

Rona Smith, Rachel Jones, Ulrich Specks et al. · Annals of the Rheumatic Diseases · 2023 · 104 citations · Full text

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 88 citations · Full text

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 74 citations · Full text